Back to top

Opko Health (OPK) Rallies on Q1 Earnings and Revenue Beat

Read MoreHide Full Article
Shares of Opko Health, Inc. (OPK - Free Report) have gained 41.9% since the release of first-quarter 2018 results on May 8. The rally was backed by a narrower-than-expected loss per share and solid pharmaceutical business. In the past three months, the stock has rallied 37.6% against the industry’s decline of 12.4%.
In the quarter under review, this Zacks Rank #3 (Hold) company incurred adjusted loss of 8 cents per share, narrower than the Zacks Consensus Estimate of a loss of 14 cents. However, the loss widened 33.3% from the prior-year quarter tally.
Quarter Highlights
Revenues in the first quarter grossed $254.9 million, which surpassed the Zacks Consensus Estimate by 2%. Nevertheless, the top line decreased from $266.4 million registered in the year-ago quarter.
Segment Details
Revenues from Services came in at $211.3 million, down 7.6% from the year-ago quarter. Per management, the downside can be attributed to volume decline of approximately 3% at the clinical lab.
Pharmaceutical Products revenues totaled $27.9 million, up 25.7% year over year. Per management, the company generated $3.7 million of revenues from sales of RAYALDEE in the reported quarter.
At Transfer of Intellectual Property, revenues raked in $15.7 million, up slightly from $15.6 million in the prior-year quarter.
In the reported quarter, gross profit totaled $100.8 million, down 9.7% on a year-over-year basis.
Gross margin was 39.5%, which contracted 240 basis points (bps).
Operating expenses amounted to $124.4 million, down 8.9% on a year-over-year basis. Notably, Opko Health incurred an operating loss of $42.6 million, down from $45.2 million in the prior-year quarter.
In the second quarter of 2018, Opko Health expects revenues from services between $205-$225 million. Product revenues are anticipated to be within $25-$30 million, including RAYALDEE revenues in the $4-$5 million band. Revenues from the transfer of intellectual property are projected between $15 million and $20 million.
Operating expenses are expected to be in line with the first quarter of 2018 at $295-$310 million range. For 2018, effective tax rate is projected to be in single digits.
Our Take
Opko Health wrapped the first quarter of 2018 on a tepid note. The company’s loss was narrower than expected, while revenues surpassed the Zacks Consensus Estimate. Moreover, the company rides on its pharmaceutical business, which registered a year-over-year increase in revenues. Also, a significant gain from RAYALDEE is noteworthy.
Furthermore, Opko Health is optimistic about its 4Kscore utilization, which witnessed solid growth in the first quarter. A year-over-year surge in the company’s R&D expenditures reflects increased focus on innovation.
However, declining margins is worrisome. Sales decline at the company’s core Service segment is an added concern.
Key Picks
A few better-ranked stocks in the broader medical space are Genomic Health (GHDX - Free Report) , Abiomed (ABMD - Free Report) and Stryker Corp. (SYK - Free Report) .
Genomic Health has an expected earnings growth rate of 187.5% for the current quarter. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Abiomed has a projected long-term earnings growth rate of 27%. The stock sports a Zacks Rank of 1.
Stryker has a projected long-term earnings growth rate of 9.7%. The stock carries a Zacks Rank #2 (Buy).
The Hottest Tech Mega-Trend of All 
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

More from Zacks Analyst Blog

You May Like

Published in